Latest Earnings Results: Q3 '26
Estimated EPS
-$0.20
Reported EPS
-$0.19
Surprise
+5.71%
Estimated Rev
$30.22M
Reported Rev
$33.54M
Surprise
+11.01%
• Reported GAAP EPS of -$0.19 up 72.46% YoY • Reported revenue of $33.55M up 68.51% YoY • Alamar Biosciences raised full-year 2026 revenue guidance to $121M to $123M, representing growth of 64% at the midpoint versus full-year 2025, from previous expectations of $116M to $120M.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.26 | -- | -- | N/A |
Q3 '26 | -$0.20 | -$0.19 | 5.71% | BEAT |
Q2 '26 | -$0.31 | -$0.22 | 28.54% | BEAT |
Q1 '26 | -$1.71 | -- | -- | N/A |